News



AB Science to present at two upcoming conferences in September 2019
12/08/2019 - AB science will present a corporate overview at two upcoming healthcare conferences in September 2019, in New York

Update on masitinib clinical program
05/08/2019 - AB Science provides an update on its masitinib clinical program

Results of masitinib study in metastatic melanoma
02/08/2019 - AB Science reports the analysis for its phase 3 trial evaluating masitinib in patients with non-resectable or metastatic stage 3 or stage 4 melanoma

AB Science Corporate Presentation
22/07/2019 - AB Science Corporate Presentation - July 2019

Summary of the webconference held on July 8, 2019
08/07/2019 - AB Science is providing a summary of the web conference held on July 8, 2019

July 8 2018 web conference presentation

08/07/2019 - AB Science web conference presentation

Publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal ALSFD

08/07/2019 - AB Science announces the publication of the positive phase 2/3 clinical trial with masitinib in ALS in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

Validation of the AB8939 clinical development plan through regulatory authority Scientific Advice procedure
04/07/2019 - AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure

Results of the Combined General Shareholders' Meeting held on June 29 2018
02/07/2019 - AB Science reports the results of the Combined General Shareholders' Meeting of June 28, 2019

Results of interim analysis for masitinib in Alzheimer's Disease
26/06/2019 - AB Science reports the outcome from the interim analysis of study AB09004 in Alzheimer's Disease

June 14 2019 web conference presentation
14/06/2019 - AB Science web conference presentation

Positive IDMC recommendation following interim analysis in pancreatic cancer
12/06/2019 - AB Science announces the positive recommendation of IDMC following the interim analysis of AB12005 study in the first-line treatment of pancreatic cancer

Updated corporate overview
10/06/2019 - AB Science is providing an updated coporate overview of the Company

Upcoming news flow
10/06/2019 - AB Science is providing the upcoming news flow of the Company

Summary of the webconference held on June 5, 2019
05/06/2019 - AB Science is providing a summary of the web conference held on 5 June, 2019

June 5 2019 web conference presentation
05/06/2019 - AB Science web conference presentation (Part 2)

Summary of the webconference held on June 4, 2019
04/06/2019 - AB Science is providing a summary of the web conference held on 4 June, 2019

June 4 2019 web conference presentation
04/06/2019 - AB Science web conference presentation (Part 1)

Web conference on June 4 and 5, 2019
30/05/2019 - AB Science will hold a web conference on its outlook for 2019 onJune 4 and 5, 2019 from 5.30 pm to 7pm CET

Lifting of the ANSM clinical hold
28/05/2019 - AB Science announces the lifting of the ANSM clinical hold

Annual financial results as of 31 December, 2018
30/04/2019 - AB Science reports its annual financial results as of 31 December 2018

Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference
16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference. Conference

Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference
21/03/2019 - AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference